Physician profile
Anna Zelichenok
NPI 1376782680
$8,006.63
in general payments reported to CMS, 2019-2025
42 companies · $2,341 in 2025
The $2,341 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,199 · 2022: $983 · 2023: $1,862 · 2024: $1,622 · 2025: $2,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,653 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,652.81 |
| Education | $171.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $870.48 | 2021-2025 | Tezspire, Fasenra, Breztri |
| Harmony Biosciences LLC | $799.71 | 2021-2025 | Wakix |
| Glaxosmithkline, LLC. | $695.87 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Pfizer INC. | $686.34 | 2021-2025 | |
| Axsome Therapeutics, INC. | $560.08 | 2023-2025 | Sunosi |
| Regeneron Healthcare Solutions, INC. | $461.24 | 2021-2025 | Dupixent, Libtayo |
| Actelion Pharmaceuticals US, INC. | $457.42 | 2021-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $418.27 | 2021-2025 | Ofev, Spiriva Respimat, Jascayd |
| Insmed, INC. | $307.00 | 2023-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $304.77 | 2021-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $254.41 | 2021-2025 | |
| Grifols USA, LLC | $250.83 | 2021-2025 | Prolastin-C Liquid |
| Amgen INC. | $241.10 | 2021-2025 | Tezspire |
| Inspire Medical Systems, INC. | $239.89 | 2023-2024 | Inspire |
| Viatris Specialty LLC | $187.69 | 2025 | Yupelri |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $149.00 | 2022 | |
| Csl Behring | $146.37 | 2022-2024 | Kcentra |
| Merck Sharp & Dohme LLC | $111.60 | 2023-2025 | Zerbaxa, Winrevair, Recarbrio |
| Genzyme Corporation | $96.50 | 2021-2025 | |
| Lilly USA, LLC | $94.50 | 2025 | Zepbound |
| Teva Pharmaceuticals USA, INC. | $74.70 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $68.71 | 2021-2023 | Xarelto |
| Baxter Healthcare | $60.69 | 2023-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Genentech USA, INC. | $56.95 | 2021 | |
| Mallinckrodt Hospital Products INC. | $47.27 | 2021-2023 | Acthar |
| Verona Pharma, INC. | $46.83 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $45.07 | 2021-2023 | Glassia |
| Avadel Cns Pharmaceuticals, LLC | $27.55 | 2024 | Lumryz |
| Electromed, INC. | $26.07 | 2024 | Smartvest |
| Novartis Pharmaceuticals Corporation | $22.76 | 2025 | |
| United Therapeutics Corporation | $20.68 | 2025 | Tyvaso |
| Bayer Healthcare Pharmaceuticals INC. | $18.90 | 2025 | |
| Cmp Pharma, INC. | $18.64 | 2023 | Tadliq |
| Philips North America LLC | $17.99 | 2024 | (Ak6) Vest Therapy |
| Fisher & Paykel Healthcare INC | $16.72 | 2024 | Fisher & Paykel Healthcare |
| Abbvie INC. | $16.23 | 2022 | |
| Mayne Pharma Commercial LLC | $16.05 | 2021 | |
| Chiesi USA, INC. | $16.01 | 2023 | Cleviprex |
| Ambu INC. | $14.64 | 2023 | |
| Paratek Pharmaceuticals, INC. | $14.09 | 2022 | |
| Azurity Pharmaceuticals, INC. | $13.86 | 2023 | Horizant |
| Resmed Corp | $13.15 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Zelichenok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.